Prevalence and Spectrum of PITX2c Mutations Associated with Congenital Heart Disease

Abstract

Congenital heart disease (CHD) is the most common form of birth defect and is the leading noninfectious cause of infant death. A growing body of evidence demonstrates that genetic risk factors are involved in the pathogenesis of CHD. However, CHD is a genetically heterogeneous disease and the genetic defects underlying CHD in an overwhelming majority of patients remain unclear. In this study, the whole coding region and splice junction sites of the PITX2c gene, which encodes variant 3 of paired-like homeodomain transcription factor 2 crucial for normal cardiovascular morphogenesis, were sequenced in 382 unrelated patients with CHD, and 2 novel heterozygous mutations, p.W147X and p.N153D, were identified in 2 unrelated patients with CHD, respectively, including a 1-year-old male patient with double outlet right ventricle in combination with ventricular septal defect and a 4-year-old female patient with ventricular septal defect. The mutations were absent in 400 control chromosomes and were both predicted to be disease-causing by MutationTaster. Multiple alignments of PITX2c proteins across species displayed that the altered amino acids were completely conserved evolutionarily. Functional analysis revealed that the mutated PITX2c proteins were associated with a significantly reduced transactivational activity compared with their wild-type counterpart. These findings provide a novel insight into the molecular mechanisms implicated in CHD, suggesting potential implications for the antenatal prophylaxis and allele-specific treatment of CHD.

Introduction

C ongenital heart disease (CHD) is the most common birth defect in humans, affecting ∼1% of newborns, and is the leading noninfectious cause of infant morbidity and mortality worldwide, accounting for about 30% of neonatal deaths resulted from developmental abnormalities (Roger et al., 2012). Various CHDs are clinically classified into at least 21 different categories with specific anatomic or hemodynamic lesions, including ventricular septal defect, atrial septal defect, atrioventricular septal defect, tetraology of Fallot, patent ductus arteriosus, aortic coarctation, pulmonary stenosis, transposition of the great arteries, and double outlet right ventricular (Roger et al., 2012). Different forms of CHD can occur separately or in combination, resulting in reduced exercise tolerance, degraded quality of life, delayed fetal brain development, subacute bacterial endocarditis, pulmonary hypertension, Eisenmenger's syndrome, thromboembolism, congestive heart failure, arrhythmias, and even sudden cardiac death (Müller et al., 2011; Shedeed and Elfaytouri, 2011; Müller et al., 2012; Murakami et al., 2012; Perry, 2012; Silka and Bar-Cohen, 2012). Therefore, CHD has conferred a heavy economic burden on patients and healthcare systems, and the socioeconomic burden continues to increase with the increasing population of adults with CHD, mainly due to advancement in cardiology and cardiac surgery (Verheugt et al., 2010). Nevertheless, the molecular mechanisms involved in the pathogenesis of CHD remain poorly understood (Bruneau, 2008; Cecchetto et al., 2010).

Embryonic heart development is an exquisitely complex and dynamic biological process that requires the orchestration of cardiac cell commitment, differentiation, proliferation, and migration, which is meticulously regulated by an evolutionarily conserved network of transcription factors that connect signaling pathways with genes for muscle growth, patterning, and contractility (Pikkarainen et al., 2004; Olson, 2006; Bruneau, 2008; Bartlett et al., 2010; Cecchetto et al., 2010), and both genetic and environmental risk factors may perturb the exquisite and coordinated interactions of transcription networks that govern cardiovascular morphogenesis, possibly leading to embryonic lethality or CHD (McCulley and Black, 2012). Moreover, mutations in multiple cardiac transcription factor genes, including GATA4, GATA5, GATA6, and NKX2-5, have been implicated in the pathogenesis of CHD (Schott et al., 1998; Garg et al., 2003; Reamon-Buettner and Borlak, 2010; Wang et al., 2012; Zheng et al., 2012; Fahed et al., 2013; Huang et al., 2013; Jiang et al., 2013; Wei et al., 2013a, 2013b; Yuan et al., 2013). However, CHD is a genetically heterogeneous disease and the molecular defects responsible for CHD in an overwhelming majority of patients remain to be identified.

Recently, a growing body of evidence indicates that the cardiac transcription factor PITX2c, a member of the paired-like homeobox family of transcription factors, plays a key role in cardiovascular genesis (Liu et al., 2002; Dagle et al., 2003; Bamforth et al., 2004; Mommersteeg et al., 2007; Galli et al., 2008; Lozano-Velasco et al., 2011). In human, the PITX2c gene is predominantly expressed in the embryonic and adult hearts (Clauss and Kääb, 2011), and is crucial for the normal embryonic development of left atrium, cardiac conduction system, and pulmonary venous myocardium (Douglas et al., 2011). In mice, deletion of PITX2c has been associated with a wide variety of CHDs, including atrial isomerism, double-outlet right ventricle, atrial septal defect, ventricular septal defect, transposition of the great artery, persistent truncus arteriosus, and abnormal aortic arch as well as incomplete closure of the body wall (Gage et al., 1999; Lin et al., 1999; Liu et al., 2001). These findings justify screening PITX2c as a prime candidate gene for CHD.

Materials and Methods

Study subjects

A cohort of 382 unrelated patients with CHD was recruited from the Chinese Han population. The available relatives of the index patients carrying the identified PITX2c mutations were also enlisted. Subjects were evaluated by individual and familial histories, review of the medical records, complete physical examination, standard 12-lead electrocardiogram, and two-dimensional transthoracic echocardiography with color flow Doppler. The types of CHD were determined using two-dimensional continuous wave Doppler and color Doppler techniques on transthoracic echocardiography. Where necessary, transesophageal echocardiography and angiography were used for further clarification of the anatomy. Some patients underwent cardiac catheterization and, if required, cardiac surgery. The patients with known chromosomal abnormalities or syndromic cardiovascular defects were excluded from the study.

A total of 200 ethnically matched, unrelated healthy individuals randomly selected from those undergoing routine physical examinations were used as controls. Based on reviews of medical histories and analyses of echocardiographic records, the control individuals had no congenital cardiovascular anomalies, except for subclinical cardiac aberrations such as a bicuspid aortic valve or a patent foramen ovale. The ethnic origin of the participants was determined by a combination of self-reported ethnicity and a personal questionnaire asking questions about the birthplace, language, religion, and ancestry.

Peripheral venous blood samples from CHD patients and control individuals were prepared. The study protocol was reviewed and approved by the local institutional ethics committee and written informed consent was obtained from all participants or their guardians before the study.

Genetic studies

Genomic DNA from all participants was extracted from blood lymphocytes with the Wizard Genomic DNA Purification Kit (Promega, Madison, WI). The whole coding region and splice junction sites of the PITX2c gene were initially sequenced in 382 unrelated patients with CHD and subsequently genotyped for the available relatives of the probands carrying identified mutations and the 200 control individuals. The referential genomic DNA sequence (accession No. NC_000004) and RNA sequence (accession No. NM_000325) of PITX2c were derived from GenBank, which was at the National Center for Biotechnical Information (NCBI; www.ncbi.nlm.nih.gov/). With the aid of the online Primer 3 program (http://frodo.wi.mit.edu), the primer pairs used to amplify the coding exons and exon/intron boundaries of PITX2c by polymerase chain reaction (PCR) were designed as previously described (Yang et al., 2013). The PCR was performed using HotStar Taq DNA Polymerase (Qiagen GmbH, Hilden, Germany) on a PE 9700 Thermal Cycler (Applied Biosystems, Foster, CA), with standard conditions and concentrations of reagents. Amplified products were analyzed on 1% agarose gels stained with ethidium bromide and purified with the QIAquick Gel Extraction Kit (Qiagen). Both strands of each PCR product were sequenced with a BigDye^® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) under an ABI PRISM 3130 XL DNA Analyzer (Applied Biosystems). The sequencing primers were the same as previously designed for specific region sequencing. The DNA sequences were viewed and analyzed with the DNA Sequencing Analysis Software v5.1 (Applied Biosystems). The sequence variation was validated by resequencing an independent PCR-generated amplicon from the subject. Additionally, for an identified PITX2c variant, the Exome Variant Server (EVS; http://evs.gs.washington.edu/EVS) and NCBI's single-nucleotide polymorphism (SNP; www.ncbi.nlm.nih.gov/SNP) online databases were queried to confirm its novelty.

Alignment of multiple PITX2c protein sequences among species

Alignment of multiple PITX2c protein sequences across various species were carried out using the online program of MUSCLE, version 3.6 (www.ncbi.nlm.nih.gov).

Prediction of the causative potential of a PITX2c sequence variation

The disease-causing potential of a PITX2c sequence variation was predicted by MutationTaster (an online program at www.mutationtaster.org), which automatically gave a probability for the variation to be either a pathogenic mutation or a benign polymorphism. Of note, the p-value used here is the probability of the correct prediction rather than the probability of error as used in t-test statistics (i.e., a value close to 1 indicates a high accuracy of the prediction).

Plasmids and site-targeted mutagenesis

The recombinant expression plasmid PITX2c-pcDNA4, which was constructed by Strungaru et al. (2011), was a gift from Prof. Georges Christé, from Physiopathologie des Troubles du Rythme Cardiaque, Faculté de Pharmacie de Lyon, Université Lyon 1, Lyon, France. The atrial natriuretic factor (ANF)-luciferase reporter plasmid, which contains the 2600-bp 5′-flanking region of the ANF gene, namely ANF(-2600)-Luc, was kindly provided by Dr. Ichiro Shiojima, from the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan. The identified mutation was introduced into the wild-type PITX2c using a QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with a complementary pair of primers. The mutant was sequenced to confirm the desired mutation and to exclude any other sequence variations.

Transcriptional activity assay

Chinese hamster ovary (CHO) cells were cultured in the Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum as well as 100 units/mL penicillin and 100 μg/mL streptomycin. The ANF(-2600)-Luc reporter construct and an internal control reporter plasmid pGL4.75 (hRluc/CMV; Promega) were used in transient transfection experiments to assay the transactivational activity of the PITX2c mutants. CHO cells were transfected with 2 μg of wild-type PITX2c–pcDNA4 or mutant PITX2c–pcDNA4 (W147×or N153D) or empty vector pcDNA4, 2.0 μg of ANF(-2600)-Luc reporter construct, and 0.04 μg of pGL4.75 control reporter vector. For cotransfection experiments, 1 μg of wild-type PITX2c–pcDNA4, 1 μg of mutant PITX2c–pcDNA4 (W147×or N153D), 2.0 μg of ANF(-2600)-Luc, and 0.04 μg of pGL4.75 were used. Transient transfection was performed 24 h after plating with Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA). The transfected cells were incubated for 24 h, then lysed, and assayed for reporter activities. Firefly luciferase and Renilla luciferase activities were measured with the Dual-Glo luciferase assay system (Promega). The activity of the ANF promoter was presented as fold activation of Firefly luciferase relative to Renilla luciferase. Three independent experiments were performed at minimum for wild-type and mutant PITX2c.

Statistical analysis

Data are expressed as means±standard deviations. Continuous variables were tested for normality of distribution, and the Student's unpaired t-test was used for comparison of numeric variables between two groups. The Pearson's χ ² test or Fisher's exact test was used, when appropriate, to compare the categorical variables between two groups. A two-tailed p<0.05 indicated statistical significance.

Results

Clinical characteristics of the study population

A cohort of 382 unrelated patients with CHD was clinically evaluated in contrast to a total of 200 ethnically matched, unrelated healthy individuals. None of them had apparent environmental risk factors for CHD, such as maternal illness and drug use in the first trimester of pregnancy, parental smoking, and chronic exposure to toxicants and ionizing radiation. The baseline clinical characteristics of the 382 patients are summarized in Table 1.

Table 1.

Baseline Clinical Characteristics of the 382 Unrelated Patients with Congenital Heart Disease

Parameter	Number or mean value	Percentage or range
Male	183	47.91
Age at the present study (year)	5.75	1–42
Age at the diagnosis of CHD (year)	3.74	0–40
Positive family history	9	2.36
Distribution of different types of CHD
Isolated CHD	276	72.25
VSD	119	31.15
ASD	95	24.87
PDA	22	5.76
PS	10	2.62
TGA	8	2.09
PTA	6	1.57
COA	5	1.31
TAPVC	5	1.31
CAVC	4	1.05
Cor triatriatum	2	0.52
Complex CHD	106	27.75
TOF	29	7.59
VSD+PFO	17	4.45
VSD+PDA	15	3.93
ASD+VSD	12	3.14
VSD+DORV	12	3.14
VSD+TGA	7	1.83
VSD+PFO+PDA	5	1.31
ASD+PDA	3	0.79
ASD+TGA	3	0.79
ASD+VSD+DORV	2	0.52
ASD+VSD+PDA	1	0.26
Incidence of arrhythmias
Atrioventricular block	23	6.02
AF	18	4.71
Treatment
Surgical repair	256	67.02
Percutaneous closure	118	30.89
Follow-up	8	2.09

CHD, congenital heart disease; ASD, atrial septal defect; VSD, ventricular septal defect; TOF, tetralogy of Fallot; PDA, patent ductus arteriosus; DORV, double outlet right ventricle; PS, pulmonary stenosis; TAPVC, total abnormal pulmonary venous connection; COA, coarctation of the aorta; TGA, transposition of the great arteries; CAVC, common arteriovenous canal; PTA, persistent truncus arteriosus; PFO, patent foramen ovale; AF, atrial fibrillation.

Identification of PITX2c sequence variations

Two heterozygous sequence variations in PITX2c were identified in 2 of 382 patients with CHD, respectively, with a mutational prevalence of ∼0.52%. Specifically, a substitution of adenine for guanine at coding nucleotide 441 of the PITX2c gene (c.441G>A), equivalent to the replacement of tryptophane by stop codon at amino acid position 147 (p.W147X), predicting the truncated protein without C-terminal 178 amino acids, was identified in the proband from family 1, a 1-year-old male patient with double outlet right ventricle in combination with ventricular septal defect. A transition of adenine to guanine in the first nucleotide of codon 153 of the PITX2c gene (c.457A>G), resulting in the transversion of asparagine to aspartic acid at amino acid 153 (p.N153D), was identified in the proband from family 2, a 4-year-old female patient with ventricular septal defect. The sequence chromatograms showing the detected heterozygous PITX2c variations in contrast to corresponding control sequences are shown in Figure 1. A schematic diagram of PITX2c showing the structural domains and the locations of the identified mutations is presented in Figure 2. The variants were neither observed in 400 control alleles nor found in the EVS and SNP databases, which were consulted again on August 3, 2013.

FIG. 1.

Sequence electropherograms showing the PITX2c mutations in contrast to their corresponding controls. The arrow indicates the heterozygous nucleotides of G/A in the probands from families 1 (A) and 2 (B), respectively (mutant), or the homozygous nucleotides of G/G (A) and A/A (B) in the corresponding control individuals (wild-type). The rectangle denotes the nucleotides comprising a codon of PITX2c.

FIG. 2.

Schematic diagram of the PITX2c protein structure with the CHD-related mutations indicated. The mutations identified in patients with CHD are shown above the structural domains. NH2, aminoterminus; TAD1, transcriptional activation domain 1 (amino acids 1–91); HD, homeodomain (amino acids 92–151); NLS, nuclear localization signal (amino acids 145–161); TID1, transcriptional inhibitory domain 1 (amino acids 162–212); TAD2, transcriptional activation domain 2 (amino acids 213–285); TID2, transcriptional inhibitory domain 2 (amino acids 286–324); COOH, carboxylterminus; CHD, congenital heart disease.

A genetic screen of the mutation carriers' family members demonstrated that in family 2, the variation was present in all affected family members available, but absent in unaffected family members examined; while in family 1, the variation was only present in the proband (III-2), and absent in his unaffected parents, indicating a de novo mutation. Analysis of the pedigrees showed that in family 2, the variation cosegregated with CHD with complete penetrance. The pedigree structures of the two families are illustrated in Figure 3. All the affected family members from both families had the same anatomic type of subarterial ventricular septal defect. The index patient from family 1 (III-2) had also double outlet right ventricle and the proband's grandfather from family 2 (I-1) had also documented atrial septal defect. The phenotypic characteristics and results of genetic screening of the affected pedigree members are listed in Table 2.

FIG. 3.

Pedigree structures of the families with CHD. Families are designated as family 1 and family 2, respectively. Family members are identified by generations and numbers. Squares indicate male family members; circles, female members; closed symbols, affected members; open symbols, unaffected members; arrows, probands; a symbol with a slash, the deceased member; “+,” carriers of the heterozygous mutations; and “−,” noncarriers.

Table 2.

Phenotypic Characteristics and Status of PITX2c Mutations of the Affected Pedigree Members

Subject information
Identity	Gender	Age (years)	Phenotypes Cardiovascular structural defects	Genotypes PITX2c mutations
Family 1				W147X
III-2	M	1	VSD, DORV	+/−
Family 2				N153D
I-1	M	62^a	VSD, ASD	NA
II-2	F	39	VSD	+/−
II-5	M	32	VSD	+/−
III-3	F	4	VSD	+/−

Age at death.

+, present; −, absent; M, male; F, female; NA, not available or not applicable.

Multiple alignments of PITX2c sequences across species

As shown in Figure 4, a cross-species alignment of multiple PITX2c protein sequences displayed that the affected amino acids were completely conserved evolutionarily, indicating that the amino acids are functionally important.

FIG. 4.

Alignment of multiple PITX2c protein sequences across species. The altered amino acids of p.W147 and p.N153 are completely conserved evolutionarily.

Disease-causing potential of PITX2c sequence variations

The PITX2c sequence variations of c.441G>A and c.457A>G were both automatically predicted to be disease-causing, with the same p-value of 1.00000. No SNPs in the altered regions were found in MutationTaster database.

Transcriptional activity of the PITX2c mutants

The wild-type PITX2c, the W147X-mutant, and the N153D-mutant PITX2c activated the ANF promoter by ∼10-, ∼3-, and ∼4-fold, respectively. When wild-type PITX2c was coexpressed with the same amount of W147X-mutant or N153D-mutant PITX2c, the induced activation of the ANF promoter was ∼7- or ∼5-fold. These results reveal that both PITX2c mutants are associated with significantly reduced activation activity compared with their wild-type counterpart (Fig. 5).

FIG. 5.

Functional impairments resulted from PITX2c mutations. Activation of ANF promoter driven luciferase reporter in CHO cells by PITX2c WT, W147X-mutant, or N153D-mutant, alone or in combination, demonstrated a significantly reduced transactivational activity by mutant proteins. Experiments were performed in triplicate, and mean and standard deviations are shown. **p<0.001 and *p<0.05, when compared with the same amount (2 μg) of wild-type PITX2c. ANF, atrial natriuretic factor; CHO, Chinese hamster ovary; WT, wild-type.

Discussion

In the present study, two novel heterozygous mutations of PITX2c, p.W147X and p.N153D, were identified in two families with CHD, respectively. The mutant alleles were present in the affected family members available, but absent in unaffected relatives examined and 400 reference chromosomes from an ethnically matched control population. A cross-species alignment of PITX2c protein sequences displayed that the altered amino acids were completely conserved evolutionarily. These two mutations were both predicted to be causative, and the functional analysis revealed that the mutant PITX2c proteins were associated with a significantly reduced transactivational activity. Therefore, it is likely that functionally impaired PITX2c predisposes to CHD in these families.

PITX2 belongs to the bicoid-like homeodomain transcription factor family. To date, four different PITX2 transcripts, generated by differential mRNA splicing and alternative promoter usage, have been identified, of which PITX2a, PITX2b, and PITX2c differ only in their amino-termini and are expressed in human, mice, chick, zebrafish, and Xenopus, whereas the fourth isoform, PITX2d, which lacks the amino-terminal domain and most of the homeodomain, is only detected in humans. The unique amino-termini of PITX2a, PITX2b, and PITX2c modify their ability to activate transcription in a cell-type and promoter-dependent manner. The homeodomain is responsible for recognizing a specific DNA sequence 5′-TAATCC-3′, which is required for DNA binding and interaction with other transcription factors. The nuclear localization signal is associated with subcellular trafficking (Simard et al., 2009). In human, PITX2c gene maps to chromosome 4q25, encoding a protein of 324 amino acids (Semina et al., 1996), and is expressed asymmetrically in the developing and adult heart, playing an important role in cardiovascular morphogenesis and maturation (Kirchhof et al., 2011). The PITX2c mutations p.W147X and p.N153D identified in this study are located in homeodomain and nuclear localization signal, respectively, and the p.W147X mutation eliminates the partial homeodomain, nuclear localization signal, and the entire C-terminus, and thus may be expected to perturb the transcriptional activation of PITX2c by interfering with the binding of PITX2c to target gene promoter or nuclear translocation.

Previous studies have established PITX2c as an upstream regulator of several target genes expressed in the heart during embryogenesis, including the gene coding for ANF (Ganga et al., 2003). Thus, the functional role of a PITX2c mutation can be explored by an assay of the transcriptional activity of the ANF promoter in tool cells. In this study, the functional characteristics of two novel PITX2c mutations identified in CHD patients were delineated by transcriptional activity analysis and the results unveiled that the two mutations were both associated with a significantly reduced transcriptional activity on a downstream gene ANF, implying that functionally compromised PITX2c is potentially an alternative pathological mechanism of CHD.

Association of functionally impaired PITX2c with increased susceptibility to congenital cardiovascular deformations has been substantiated in animal models. In mice, PITX2c was expressed predominantly in the trabecular and septal myocardium with a strong expression bias in the myocardium associated with endocardial cushions of the atrioventricular canal and outflow tract (Furtado et al., 2001), and knockout of the PITX2c gene resulted in embryonic death, due to cardiovascular defects, including double-outlet right ventricle, atrial isomerism, atrial septal defect, ventricular septal defect, and abnormal aortic arch (Liu et al., 2001). In Xenopus, knockdown of PITX2c by RNA interference led to defects in the cardiac outflow tract and cardiac septation (Dagle et al., 2003). These experimental findings highlight an exquisite sensitivity of the developing cardiovascular system to the level of PITX2c.

It has been demonstrated that during embryogenesis, multiple genes are transactivated by PITX2c (Clauss and Kääb, 2011), and genetic mutations in several downstream target molecules have been linked to CHD, including GATA4, NKX2.5, CX40, and CX43 (Britz-Cunningham et al., 1995; Schott et al., 1998; Garg et al., 2003; Krüger et al., 2006; Soemedi et al., 2012). Hence, mutated PITX2c may enhance the vulnerability to CHD by decreasing the expressions of such cardiac-specific target genes.

In addition, by exome sequencing, Zaidi et al. (2013) previously screened 362 patients with sporadic CHD, including 154 with conotruncal defects, 132 with left ventricular obstruction, 70 with heterotaxy, and 6 with other cardiac structural deformations, and found a de novo mutation in PITX2c, p.A47V, in a patient with left ventricular obstruction (coarctation of the aorta), with a mutational prevalence of roughly 0.28%. However, the functional characteristics of the PITX2 mutation associated with idiopathic coarctation of the aorta remain to be delineated.

It was interesting that PITX2c mutations were related to lone atrial fibrillation (AF). Yang et al. (2013) genotyped PITX2c in 152 unrelated index patients with familial AF and their available relatives, and identified two novel heterozygous PITX2c mutations, p.S37W and p.Y280X, in two families with AF, respectively. Zhou et al. (2013) sequenced PITX2c in 100 unrelated patients with lone AF, and found a novel heterozygous PITX2c mutation, p.T97A, in a patient with AF. Functional analysis revealed that the T97A-mutant PITX2c was associated with a significantly decreased transcriptional activity. However, no CHD was observed in these patients with AF-associated PITX2c mutations. Similarly, in mice heterozygous for Pitx2c with left atrial Pitx2c expression being 60% of wild type, the cardiac morphology and function were not altered, but the isolated hearts were susceptible to AF during programmed stimulation (Kirchhof et al., 2011). The pronounced phenotypic variability may be explained by the following reasons. First, AF occurs as rarely as a few times in a lifetime for some patients with AF, suggesting a longer duration of electrocardiographic monitoring required to record paroxysmal AF in our patients. Next, AF occurs more commonly in older patients, and some carriers may not be old enough to develop the disease. Third, considering some congenital cardiac structural defects may close spontaneously, we cannot rule out the possibility that some mutation carriers with lone AF had minor cardiac septal defects that closed shortly after birth on their own. Fourth, the nature of a mutation and its temporal and spatial effects during cardiac development are a potential explanation for this phenomenon (Benson et al., 1999). Fifth, different genetic backgrounds, including possibly common SNPs altering disease susceptibility, contribute to the variable penetrance of the phenotype. Finally, some mutations may be only a genetic risk factor predisposing to a certain disease, rather than a direct cause, and environmental risk factors may be needed for the onset of the disease.

Conclusion

In conclusion, the present study at first associates PITX2c loss-of-function mutations with congenital ventricular septal defect and double outlet right ventricle in humans, which provides novel insight into the molecular mechanism of CHD, and suggests potential implications for early prophylaxis and allele-specific therapy of CHD.

Footnotes

Acknowledgments

The authors are really thankful to the participants for their devotion to the study. This work was supported, in part, by grants from the National Natural Science Fund of China (81070153, 81270161, and 81271927), the Personnel Development Foundation of Shanghai, China (2010019), the Natural Science Fund of Shanghai, China (10ZR1428000), and the Key Program of Basic Research of Shanghai, China (10JC1414002).

Disclosure Statement

No competing financial interests exist.

References

Bamforth

S.D.

, Bragança

, Farthing

C.R.

, Schneider

J.E.

, Broadbent

, Michell

A.C.

, Clarke

, Neubauer

, Norris

, Brown

N.A.

, Anderson

R.H.

, Bhattacharya

2004. Cited2 controls left-right patterning and heart development through a Nodal-Pitx2c pathway. Nat Genet, 36:1189–1196.

Bartlett

, Veenstra

G.J.

, Weeks

D.L.

2010. Examining the cardiac NK-2 genes in early heart development. Pediatr Cardiol, 31:335–341.

Benson

D.W.

, Silberbach

G.M.

, Kavanaugh-McHugh

, Cottrill

, Zhang

, Riggs

, Smalls

, Johnson

M.C.

, Watson

M.S.

, Seidman

J.G.

, Seidman

C.E.

, Plowden

, Kugler

J.D.

1999. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest, 104:1567–1573.

Britz-Cunningham

, Shah

, Zuppan

, Fletcher

1995. Mutations of the connexin43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med, 332:1323–1329.

Bruneau

B.G.

2008. The developmental genetics of congenital heart disease. Nature, 451:943–948.

Cecchetto

, Rampazzo

, Angelini

, Bianco

L.D.

, Padalino

, Stellin

, Daliento

2010. From molecular mechanisms of cardiac development to genetic substrate of congenital heart diseases. Future Cardiol, 6:373–393.

Clauss

, Kääb

2011. Is Pitx2 growing up? Circ Cardiovasc Genet, 4:105–107.

Dagle

J.M.

, Sabel

J.L.

, Littig

J.L.

, Sutherland

L.B.

, Kolker

S.J.

, Weeks

D.L.

2003. Pitx2c attenuation results in cardiac defects and abnormalities of intestinal orientation in developing Xenopus laevis. Dev Biol, 262:268–281.

Douglas

Y.L.

, Jongbloed

M.R.

, Deruiter

M.C.

, Gittenberger-de Groot

A.C.

2011. Normal and abnormal development of pulmonary veins: state of the art and correlation with clinical entities. Int J Cardiol, 147:13–24.

10.

Fahed

A.C.

, Gelb

B.D.

, Seidman

J.G.

, Seidman

C.E.

2013. Genetics of congenital heart disease: the glass half empty. Circ Res, 112:707–720.

11.

Furtado

M.B.

, Biben

, Shiratori

, Hamada

, Harvey

R.P.

2001. Characterization of Pitx2c expression in the mouse heart using a reporter transgene. Dev Dyn, 240:195–203.

12.

Gage

P.J.

, Suh

, Camper

S.A.

1999. Dosage requirement of Pitx2 for development of multiple organs. Development, 126:4643–4651.

13.

Galli

, Domínguez

J.N.

, Zaffran

, Munk

, Brown

N.A.

, Buckingham

M.E.

2008. Atrial myocardium derives from the posterior region of the second heart field, which acquires left-right identity as Pitx2c is expressed. Development, 135:1157–1167.

14.

Ganga

, Espinoza

H.M.

, Cox

C.J.

, Morton

, Hjalt

T.A.

, Lee

, Amendt

B.A.

2003. PITX2 isoform-specific regulation of atrial natriuretic factor expression: synergism and repression with Nkx2.5. J Biol Chem, 278:22437–22445.

15.

Garg

, Kathiriya

I.S.

, Barnes

, Schluterman

M.K.

, King

I.N.

, Butler

C.A.

, Rothrock

C.R.

, Eapen

R.S.

, Hirayama-Yamada

, Joo

, Matsuoka

, Cohen

J.C.

, Srivastava

2003. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature, 424:443–447.

16.

Huang

R.T.

, Xue

, Xu

Y.J.

, Yang

Y.Q.

2013. Somatic mutations in the GATA6 gene underlie sporadic tetralogy of Fallot. Int J Mol Med, 31:51–58.

17.

Jiang

J.Q.

, Li

R.G.

, Wang

, Liu

X.Y.

, Xu

Y.J.

, Fang

W.Y.

, Chen

X.Z.

, Zhang

, Wang

X.Z.

, Yang

Y.Q.

2013. Prevalence and spectrum of GATA5 mutations associated with congenital heart disease. Int J Cardiol, 165:570–573.

18.

Kirchhof

, Kahr

P.C.

, Kaese

, Piccini

, Vokshi

, Scheld

H.H.

, Rotering

, Fortmueller

, Laakmann

, Verheule

, Schotten

, Fabritz

, Brown

N.A.

2011. PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet, 4:123–133.

19.

Krüger

, Maxeiner

, Kim

J.S.

, van Rijen

H.V.

, de Bakker

J.M.

, Eckardt

, Tiemann

, Lewalter

, Ghanem

, Lüderitz

, Willecke

2006. Cardiac morphogenetic defects and conduction abnormalities in mice homozygously deficient for connexin40 and heterozygously deficient for connexin45. J Mol Cell Cardiol, 41:787–797.

20.

Lin

C.R.

, Kioussi

, O'Connell

, Briata

, Szeto

, Liu

, Izpisúa-Belmonte

J.C.

, Rosenfeld

M.G.

1999. Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Nature, 401:279–282.

21.

Liu

, Liu

, Lu

M.F.

, Brown

N.A.

, Martin

J.F.

2001. Regulation of left-right asymmetry by thresholds of Pitx2c activity. Development, 128:2039–2048.

22.

Liu

, Liu

, Palie

, Lu

M.F.

, Brown

N.A.

, Martin

J.F.

2002. Pitx2c patterns anterior myocardium and aortic arch vessels and is required for local cell movement into atrioventricular cushions. Development, 129:5081–5091.

23.

Lozano-Velasco

, Chinchilla

, Martínez-Fernández

, Hernández-Torres

, Navarro

, Lyons

G.E.

, Franco

, Aránega

A.E.

2011. Pitx2c modulates cardiac-specific transcription factors networks in differentiating cardiomyocytes from murine embryonic stem cells. Cells Tissues Organs, 194:349–362.

24.

McCulley

D.J.

, Black

B.L.

2012. Transcription factor pathways and congenital heart disease. Curr Top Dev Biol, 100:253–277.

25.

Mommersteeg

M.T.

, Brown

N.A.

, Prall

O.W.

, de Gier-de Vries

, Harvey

R.P.

, Moorman

A.F.

, Christoffels

V.M.

2007. Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ Res, 101:902–909.

26.

Müller

, Hess

, Hager

2011. Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis. Int J Cardiol, 150:177–181.

27.

Müller

, Hess

, Hager

2012. Minor symptoms of depression in patients with congenital heart disease have a larger impact on quality of life than limited exercise capacity. Int J Cardiol, 154:265–269.

28.

Murakami

, Niwa

, Yoshinaga

, Nakazawa

2012. Factors associated with surgery for active endocarditis in congenital heart disease. Int J Cardiol, 157:59–62.

29.

Olson

E.N.

2006. Gene regulatory networks in the evolution and development of the heart. Science, 313:1922–1927.

30.

Perry

J.C.

2012. Sudden cardiac death and malignant arrhythmias: the scope of the problem in adult congenital heart patients. Pediatr Cardiol, 33:484–490.

31.

Pikkarainen

, Tokola

, Kerkelä

, Ruskoaho

2004. GATA transcription factors in the developing and adult heart. Cardiovasc Res, 63:196–207.

32.

Reamon-Buettner

S.M.

, Borlak

2010. NKX2-5: an update on this hypermutable homeodomain protein and its role in human congenital heart disease (CHD) Hum Mutat, 31:1185–1194.

33.

Roger

V.L.

, Go

A.S.

, Lloyd-Jones

D.M.

, Benjamin

E.J.

, Berry

J.D.

, Borden

W.B.

, Bravata

D.M.

, Dai

, Ford

E.S.

, Fox

C.S.

, Fullerton

H.J.

, Gillespie

, Hailpern

S.M.

, Heit

J.A.

, Howard

V.J.

, Kissela

B.M.

, Kittner

S.J.

, Lackland

D.T.

, Lichtman

J.H.

, Lisabeth

L.D.

, Makuc

D.M.

, Marcus

G.M.

, Marelli

, Matchar

D.B.

, Moy

C.S.

, Mozaffarian

, Mussolino

M.E.

, Nichol

, Paynter

N.P.

, Soliman

E.Z.

, Sorlie

P.D.

, Sotoodehnia

, Turan

T.N.

, Virani

S.S.

, Wong

N.D.

, Woo

, Turner

M.B.

American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2012. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation, 125:e2–e220.

34.

Schott

J.J.

, Benson

D.W.

, Basson

C.T.

, Pease

, Silberbach

G.M.

, Moak

J.P.

, Maron

B.J.

, Seidman

C.E.

, Seidman

J.G.

1998. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science, 281:108–111.

35.

Semina

E.V.

, Reiter

, Leysens

N.J.

, Alward

W.L.

, Small

K.W.

, Datson

N.A.

, Siegel-Bartelt

, Bierke-Nelson

, Bitoun

, Zabel

B.U.

, Carey

J.C.

, Murray

J.C.

1996. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet, 14:392–399.

36.

Shedeed

S.A.

, Elfaytouri

2011. Brain maturity and brain injury in newborns with cyanotic congenital heart disease. Pediatr Cardiol, 32:47–54.

37.

Silka

M.J.

, Bar-Cohen

2012. A contemporary assessment of the risk for sudden cardiac death in patients with congenital heart disease. Pediatr Cardiol, 33:452–460.

38.

Simard

, Di Giorgio

, Amen

, Westwood

, Amendt

B.A.

, Ryan

A.K.

2009. The Pitx2c N-terminal domain is a critical interaction domain required for asymmetric morphogenesis. Dev Dyn, 238:2459–2470.

39.

Soemedi

, Topf

, Wilson

I.J.

, Darlay

, Rahman

, Glen

, Hall

, Huang

, Bentham

, Bhattacharya

, Cosgrove

, Brook

J.D.

, Granados-Riveron

, Setchfield

, Bu'lock

, Thornborough

, Devriendt

, Breckpot

, Hofbeck

, Lathrop

, Rauch

, Blue

G.M.

, Winlaw

D.S.

, Hurles

, Santibanez-Koref

, Cordell

H.J.

, Goodship

J.A.

, Keavney

B.D.

2012. Phenotype-specific effect of chromosome 1q21.1 rearrangements and GJA5 duplications in 2436 congenital heart disease patients and 6760 controls. Hum Mol Genet, 21:1513–1520.

40.

Strungaru

M.H.

, Footz

, Liu

, Berry

F.B.

, Belleau

, Semina

E.V.

, Raymond

, Walter

M.A.

2011. PITX2 is involved in stress response in cultured human trabecular meshwork cells through regulation of SLC13A3. Invest Ophthalmol Vis Sci, 52:7625–7633.

41.

Verheugt

C.L.

, Uiterwaal

C.S.

, van der Velde

E.T.

, Meijboom

F.J.

, Pieper

P.G.

, Sieswerda

G.T.

, Plokker

H.W.

, Grobbee

D.E.

, Mulder

B.J.

2010. The emerging burden of hospital admissions of adults with congenital heart disease. Heart, 96:872–878.

42.

Wang

, Luo

X.J.

, Xin

Y.F.

, Liu

Z.M.

, Wang

, Li

R.G.

, Fang

W.Y.

, Wang

X.Z.

, Yang

Y.Q.

2012. Novel GATA6 mutations associated with congenital ventricular septal defect or tetralogy of fallot. DNA Cell Biol, 31:1610–1617.

43.

Wei

, Bao

, Liu

X.Y.

, Zhou

, Wang

, Li

R.G.

, Xu

Y.J.

, Yang

Y.Q.

2013a. GATA5 loss-of-function mutations underlie tetralogy of fallot. Int J Med Sci, 10:34–42.

44.

Wei

, Bao

, Zhou

, Zheng

G.F.

, Liu

X.Y.

, Yang

Y.Q.

2013b. GATA5 loss-of-function mutation responsible for the congenital ventriculoseptal defect. Pediatr Cardiol, 34:504–511.

45.

Yang

Y.Q.

, Xu

Y.J.

, Li

R.G.

, Qu

X.K.

, Fang

W.Y.

, Liu

2013. Prevalence and spectrum of PITX2c mutations associated with familial atrial fibrillation. Int J Cardiol[Epub ahead of print];10.1016/j.ijcard.2013.03.141.

46.

Yuan

, Zaidi

, Brueckner

2013. Congenital heart disease: emerging themes linking genetics and development. Curr Opin Genet Dev, 23:352–359.

47.

Zaidi

, Choi

, Wakimoto

, Ma

, Jiang

, Overton

J.D.

, Romano-Adesman

, Bjornson

R.D.

, Breitbart

R.E.

, Brown

K.K.

, Carriero

N.J.

, Cheung

Y.H.

, Deanfield

, DePalma

, Fakhro

K.A.

, Glessner

, Hakonarson

, Italia

M.J.

, Kaltman

J.R.

, Kaski

, Kim

, Kline

J.K.

, Lee

, Leipzig

, Lopez

, Mane

S.M.

, Mitchell

L.E.

, Newburger

J.W.

, Parfenov

, Pe'er

, Porter

, Roberts

A.E.

, Sachidanandam

, Sanders

S.J.

, Seiden

H.S.

, State

M.W.

, Subramanian

, Tikhonova

I.R.

, Wang

, Warburton

, White

P.S.

, Williams

I.A.

, Zhao

, Seidman

J.G.

, Brueckner

, Chung

W.K.

, Gelb

B.D.

, Goldmuntz

, Seidman

C.E.

, Lifton

R.P.

2013. De novo mutations in histone-modifying genes in congenital heart disease. Nature, 498:220–223.

48.

Zheng

G.F.

, Wei

, Zhao

, Zhou

, Yang

Y.Q.

, Liu

X.Y.

2012. A novel GATA6 mutation associated with congenital ventricular septal defect. Int J Mol Med, 9:1065–1071.

49.

Zhou

Y.M.

, Zheng

P.X.

, Yang

Y.Q.

, Ge

Z.M.

, Kang

W.Q.

2013. A novel PITX2c loss-of-function mutation underlies lone atrial fibrillation. Int J Mol Med, 32:827–834.